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Melanoma Incidence and Lethality Is
Increased Following Solid Organ
Transplantation
David C. Whiteman1,2 and Catherine M. Olsen1,2
Organ transplants save lives, but the risks of adverse health outcomes
remain high. Robbins et al. (2015) report the ﬁndings of a record-linkage
study that followed almost 140,000 organ transplant recipients (OTRs) for
melanoma. They found higher risk of incident melanoma among OTRs and
markedly increased lethality. Education and surveillance are key to mitigating
these effects.
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About 28,000 organ transplants occur in
the United States each year, and more
than 600,000 Americans have received a
transplanted organ since 1988. Organ
transplant recipients (OTRs) are survi-
ving longer than previously, prompting
research into the health trajectory of
patients after transplantation, especially
for life-threatening illnesses. Previous
research has shown that OTRs have
signiﬁcantly higher risk of developing
certain cancers than the general popula-
tion, especially those cancers known
or suspected to have an infectious
cause (Grulich et al., 2007), and it has
been presumed that this reﬂects the
effects of prolonged immune suppres-
sion following transplantation to prevent
rejection of the donated organ. Over the
past few decades, a growing body of
literature has suggested that OTRs also
have a higher incidence of melanoma
than the general population (Green and
Olsen, 2015), and, further, that melano-
mas arising in OTRs have a more aggres-
sive course, culminating in shorter
survival (Vajdic et al., 2014; Krynitz
et al., 2015). In this issue of the Journal
of Investigative Dermatology, Robbins
et al., (2015) report the ﬁndings of a
large record-linkage study that was
designed to investigate melanoma inci-
dence and mortality in US transplant
recipients.
The team performed two separate
analyses, the ﬁrst investigating melanoma
incidence among OTRs and the second
investigating mortality and survival fol-
lowing transplantation. The incidence
analysis presented here extends an earlier
investigation by the same group (Engels
et al., 2011) and is the largest such study
to date, comprising 519 invasive and
190 in situ melanomas. The earlier
study linked all patients in the Scientiﬁc
Registry of Transplant Recipients to
13 population-based cancer registries to
identify diagnoses of melanoma occur-
ring subsequent to transplantation. The
new study includes 3–4 more years
of cancer registry data for 9 of these 13
registries, as well as previously unlinked
cancer data from two additional regis-
tries. Details of melanoma stage and
anatomic site were available for analysis,
as were demographic (age, sex, place
of residence, etc) and clinical (year of
transplant, organ, etc) details. Melanoma
incidence in the OTR cohort was then
compared with the incidence prevailing
in the general population during the
period of observation, with additional
analyses to explore factors associated
with increased risk. The second analysis
used cause of death data available from
six of the cancer registries to compare
survival and melanoma-speciﬁc mortality
following a ﬁrst diagnosis of cutaneous
melanoma among OTRs and the general
population.
Organ transplantation confers higher
risks of incident melanoma
The incidence analysis found that the
age- and sex-adjusted rates of melanoma
in the cohort of transplant patients were
2.2-fold higher than the general popula-
tion, slightly lower than the summary risk
estimate of 2.71 (95% conﬁdence inter-
val (CI) 2.23–3.30) reported by a recent
meta-analysis of 20 cohort studies (Green
and Olsen, 2015). Novel ﬁndings in the
new analysis include relatively higher
rates of regional stage melanomas
(standardized incidence ratio 4.4; 95%
CI 3.27–5.09) and those occurring on the
head and neck (standardized incidence
ratio 3.34; 95% CI 2.85–3.90). The
higher risks of regional and distant stage
melanoma observed in the immediate
post-transplant period when the state of
immunosuppression is greatest are con-
sistent with the ﬁndings of others (Vajdic
et al., 2009; Bilmon et al., 2014).
The elevated incidence of melanoma
among transplant recipients may partly
reﬂect heightened medical surveillance
(Welch and Black, 2010), since OTRs are
widely known to have very high risks of
cutaneous squamous cell carcinoma and,
thus, are arguably more likely than
the general population to receive
dermatologic surveillance. Because this
recent analysis used clinical information
from large-scale data sets, information on
key melanoma risk factors such as skin
type, ethnicity, numbers of melanocytic
nevi, family history, and individual-level
sun exposure were not available.
Although it is possible that the risk
estimates for transplantation in the pre-
sent analysis are confounded, this is
unlikely in practice, since the causal
factors above are not known to be more
or less prevalent among patients under-
going organ transplantation. Similarly,
‘confounding by indication’, whereby
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the underlying medical conditions
that precipitated the need for organ
transplantation are primarily responsible
for conferring an increased risk of mela-
noma, is also possible in theory but
unlikely in practice. The increased mel-
anoma incidence among transplant reci-
pients is analogous with the higher rates
observed in other patient groups with
compromised immunity, such as those
with HIV infection/AIDS (Olsen et al.,
2014), lymphoproliferative disorders,
including non-Hodgkins lymphoma
(Pirani et al., 2011), and those with
other conditions treated with
immunosuppressant therapies, including
inﬂammatory bowel disease (McKenna
et al., 2014) and rheumatoid arthritis
(Wolfe and Michaud, 2007). Taken
together, the increased incidence of
melanoma observed among transplant
recipients is most likely explained by
the immunosuppressive therapy.
The authors speculated that medica-
tions that increase ultraviolet radiation
(UVR)-induced DNA damage (speciﬁ-
cally azathioprine) may be responsible
for the increased risk of localized
melanomas, although aside from a
marginally raised risk estimate, the results
of this observational record linkage study
provide no direct evidence to support this
possibility. It is the case that the Interna-
tional Agency for Research on Cancer has
declared azathioprine a Group 1 carcino-
gen for cutaneous squamous cell carci-
noma (IARC Working Group on the
Evaluation of Carcinogenic Risks to
Humans, 2012), but prospective studies
reporting on the association between
azathioprine use and melanoma have
been limited and inconsistent. The few
available studies have used different
deﬁnitions of exposure and different
groups for comparison (Gallagher et al.,
2010; Watorek et al., 2011), and so it
remains uncertain whether azathioprine
is associated with a greater risk of
melanoma than other immunosup-
pressant drugs. Furthermore, the studies
investigating melanoma outcomes span a
considerable period of time (from the
1960s onwards), during which there have
been numerous changes in treatment
regimes. Pooled analyses may provide
more power to address these questions.
Melanomas in transplant patients are
more often lethal
Robbins et al., (2015) also found that
following a diagnosis of melanoma, OTRs
had signiﬁcantly higher risk of dying
from their tumors (about 3-fold) than the
general population, similar in magni-
tude to estimates from smaller studies
conducted in Australia (Vajdic et al.,
2014) and Sweden (Krynitz et al., 2015).
In the US study, mortality hazards was
highest for localized and regional
melanomas; the risk of dying from
localized tumors was more than 4-fold
higher for OTRs than non-recipients,
whereas the risk of dying from distant
melanomas did not differ signiﬁcantly
between OTRs and the general popula-
tion. Thin melanomas typically have a
favorable prognosis (Green et al., 2012),
and so the observation that OTRs were
more than 4-fold more likely to die from
a thin melanoma (o1mm) than non-
recipients was especially troubling.
Granted, this effect estimate was impre-
cise owing to the small number of OTRs
with thin melanomas who died from their
disease, but it was nonetheless statistically
signiﬁcant. While bias must always be
considered as an explanation for ﬁndings
arising from observational epidemiologic
studies, it is difﬁcult to mount a plausible
argument to disregard these strikingly
higher melanoma-speciﬁc mortality data
for transplant patients. There is no reason
to expect that cause of death would be
reported or recorded differently for OTRs
than the general population. Even if this
did occur, one would expect such biased
reporting to be more pronounced in the
early years following transplantation
when the event might be accorded
greater prominence than many years
later. Assuming the higher mortality and
poorer survival of OTRs with melanoma
is real, the question is why?
Melanomas are highly immunogenic
tumors (Kubica and Brewer, 2012),
probably due to the very high load of
UVR-induced mutations within the gen-
ome and consequent production of neo-
antigens (McArthur and Ribas, 2013).
Recent breakthroughs in understanding
the complexity of tumor-host interactions
in melanoma have led to the discovery of
novel immune therapies that underscore
the important role of the immune system
in checking the growth and spread
of these cancers. In this context, the
observation that melanomas arising in
OTRs are associated with signiﬁcantly
poorer survival than melanomas in non-
transplanted patients, even after adjusting
for known prognostic factors, are consis-
tent with the explanation that suppression
of the immune system allows melanomas
to escape the usual control mechanisms
that strive to keep these tumors in check,
thereby increasing the risk of metastasis
and death. Given that UVR induces local
and systemic immune suppression (Hart
et al., 2011) and that UVR also causes the
mutations that initiate melanomagenesis
and inﬂuence tumor behavior (Hodis
et al., 2012), the underlying mediators
of immune suppression on melanoma
development are likely to be complex
and to involve interaction with many
pathways. Cataloguing the types and
frequencies of driver mutations in mela-
nomas arising in OTRs would be one
logical step to move the ﬁeld forward.
There is no doubt that the ﬁeld of
melanoma is currently undergoing seismic
changes in knowledge (No authors listed,
2015). New treatment options are offering
fresh hope to patients with previously
incurable disease, and early detection
efforts in many settings are reducing the
proportion of people presenting with thick
lesions. On a background of such wide-
spread optimism, it is, thus, sobering to be
reminded of a group of patients for whom
Clinical Implications
● Following organ transplantation, the risks of developing melanoma are
more than doubled.
● Melanomas in organ transplant recipients (OTRs) are 3-fold more likely to
be lethal.
● OTRs require education, close surveillance and prompt management of
pigmented lesions.
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melanomas exact a disproportionate toll.
The data from these analyses provide
strong grounds for enacting policies of
melanoma education, primary prevention
and close surveillance for all patients
undergoing organ transplantation.
Suspicious pigmented lesions should be
managed promptly in all such patients. For
OTRs diagnosed with melanoma, referral
to expert centers would seem prudent.
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CYR61/CCN1: A Novel Mediator of
Epidermal Hyperplasia and
Inﬂammation in Psoriasis?
Taihao Quan1, Andrew Johnston1, Johann E. Gudjonsson1 and
Gary J. Fisher1
The complex pathogenesis of psoriasis is still not fully understood. The study by
Sun et al. (2015) suggests that CYR61 (now named CCN1), a secreted
matricellular protein, has a role in the pathogenesis of psoriasis, and thus
targeting CCN1 represents a potential therapeutic strategy in its treatment.
Journal of Investigative Dermatology (2015) 135, 2562–2564. doi:10.1038/jid.2015.300
CCN1 in psoriasis: new ﬁndings and
clinical implications
Psoriasis is a chronic inﬂammatory skin
disease characterized by hyperprolifera-
tion of epidermal keratinocytes and result-
ing in scaly, red, and well-demarcated
skin lesions. Hyperproliferation is driven
by the additive and synergistic activities of
a plethora of cytokines and growth factors
(Baliwag et al., 2015) acting on and
driving changes in the architecture of
the epidermis, keratinocytes, resident and
inﬁltrating immune cells, as well as
ﬁbroblasts and vascular endothelium in
the dermis (Elder et al., 2010). In this
issue, Sun et al., (2015) add another
ingredient to the inﬂammatory recipe
responsible for driving this disease;
they report that the expression of CCN1,
a multifunctional non-structural protein
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